Clinical Trials in New York

Showing 16701-16720 of 22,668 trials

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

NCT01538537

The primary objective of this study is to determine the largest dose of ON 01910.Na (rigosertib sodium) that can be given safely as a 3-day continuous infusion once every 2 weeks (2-week cycle) in patients with advanced cancer.

Advanced CancerSolid TumorsCancer+1 more

Traws Pharma, Inc.29 participantsStarted Aug 2006

New York, New York, United States

COMPLETEDPhase 1< 1 mile

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

NCT01048619

In other clinical studies, ON 01910.Na has been safely given intravenously to Patients with advanced cancers. However, to treat some Patients, it may be better if ON 01910.Na could be given by mouth. This study will determine if it is safe to give ON 01910.Na by mouth, what is the highest dose can be safely given by mouth, and how much of the drug gets from the stomach into the blood stream when it is given by mouth.

Myelodysplastic Syndrome

Traws Pharma, Inc.36 participantsStarted Dec 2009

Tampa, Florida, United States • New York, New York, United States

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Find Trials by Condition in New York

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

BioFiber Scaffold Post-Market Observational Study

Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

The Northern-European Initiative on Colorectal Cancer

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)